

Erasmus MC

Universitair Medisch Centrum Rotterdam



21st CardioVascular Summit

TCTAP 2016

April 26-29, 2016
Coex, Seoul, Korea

OCT&Pressure Wire-Guided Comprehensive Assessment for Coronary Artery Disease

Vulnerability Assessment Using OCT



***Evelyn Regar
Thoraxcenter
Erasmus Medical Center
Rotterdam, The Netherlands***

Disclosure




The institution Erasmus Medical Center receives research support from St. Jude Medical & consultancy fees from Boston Scientific.



Plaque Prone to Rupture

Inflamed, thin-cap fibroatheroma (TCFA)

- ❑ Lipid-rich, atheromatous core
- ❑ Thin fibrous cap, with
- ❑ Macrophage and lymphocyte infiltration
- ❑ Decreased SMC content
- ❑ Expansive remodeling




- OCT can visualize different plaque components: in vitro

	<i>Sens.</i>	<i>Spec.</i>
<i>Fibrous</i>	<i>71-79%</i>	<i>97-98%</i>
<i>Fibro-calcific</i>	<i>95-96%</i>	<i>97%</i>
<i>Lipid-rich</i>	<i>90-94%</i>	<i>90-92%</i>

Overall agreement $k = 0.83$ to 0.84


OCT Assessment of Vulnerability

- OCT can visualize lipid rich-plaque.




OCT Assessment of Vulnerability

- OCT can visualize lipid rich-plaque.




OCT Assessment of Vulnerability


- OCT can visualize lipid rich-plaque.
- OCT can visualize the thickness of a fibrous cap.



- OCT can visualize lipid rich-plaque.
- OCT can quantify the thickness of a fibrous cap (automated).




**Fully automated segmentation
of fibrous cap thickness**




OCT Assessment of Vulnerability

- OCT can visualize lipid rich-plaque.
- OCT can visualize a thin fibrous cap.
- OCT can differentiate thrombus.



OCT Assessment of Vulnerability

- OCT can visualize lipid rich-plaque.
- OCT can visualize a thin fibrous cap.
- OCT can differentiate thrombus.



	peak intensity	$\frac{1}{2}$ width (μm)
red	130 ± 18	183 ± 42
white	145 ± 34	324 ± 50
P-value	0.12	0.0001

OCT Assessment of Vulnerability



- OCT can visualize lipid rich-plaque.
- OCT can visualize a thin fibrous cap.
- OCT can differentiate thrombus.
- OCT can diagnose thin cap fibroatheroma (TCFA)

	TCFA (n=30)	Non-TCFA (n=47)	P value
IVUS findings			
Reference site			
EEM CSA, mm ²	14.7±6.2	12.6±3.9	0.064
Lumen CSA, mm ²	6.4±3.0	5.4±1.9	0.094
Plaque plus media CSA, mm ²	8.3±3.8	7.2±2.5	0.108
Lesion site			
EEM CSA, mm ²	15.3±6.1	13.4±4.2	0.110
Lumen CSA, mm ²	4.4±2.2	4.0±1.6	0.332
Plaque plus media CSA, mm ²	10.9±4.3	9.4±3.2	0.086
Plaque burden, %	71±7	70±7	0.636
Remodeling index	1.06±0.11	1.08±0.15	0.463
Positive remodeling, n (%)	15 (50%)	29 (62%)	0.157
OCT findings			
TCFA detected by OCT	27 (90%)		
Thickness of the fibrous cap, μm	46±32		

OCT Assessment of Vulnerability


- OCT can visualize lipid rich-plaque.
- OCT can visualize a thin fibrous cap.
- OCT can differentiate thrombus.
- OCT can diagnose thin cap fibroatheroma (TCFA)

	TCFA (n=30)	Non-TCFA (n=47)	P value
IVUS findings			
Reference site			
EEM CSA, mm ²	14.7±6.2	12.6±3.9	0.064
Lumen CSA, mm ²	6.4±3.0	5.4±1.9	0.094
Plaque plus media CSA, mm ²	8.3±3.8	7.2±2.5	0.108
Lesion site			
EEM CSA, mm ²	15.3±6.1	13.4±4.2	0.110
Lumen CSA, mm ²	4.4±2.2	4.0±1.6	0.332
Plaque plus media CSA, mm ²	10.9±4.3	7.4±3.2	0.086
Plaque burden, %	71±7	67±7	0.636
Remodeling index	1.06±0.11	1.08±0.15	0.463
Positive remodeling, n (%)	15 (50%)	29 (62%)	0.157
OCT findings			
TCFA detected by OCT	27 (90%)		
Thickness of the fibrous cap, μm	46±32		




90%

OCT Assessment of Vulnerability

- *OCT can visualize lipid rich-plaque.*
- *OCT can visualize a thin fibrous cap.*
- *OCT can differentiate thrombus.*
- *OCT can diagnose thin cap fibroatheroma (TCFA)*
- **OCT can visualize plaque changes over time**



- *OCT can visualize lipid rich-plaque.*
- *OCT can visualize a thin fibrous cap.*
- *OCT can differentiate thrombus.*
- *OCT can diagnose thin cap fibroatheroma (TCFA)*
- **OCT can visualize plaque changes over time**




*porcine
coronary artery*




- *OCT can visualize lipid rich-plaque.*
- *OCT can visualize a thin fibrous cap.*
- *OCT can differentiate thrombus.*
- *OCT can diagnose thin cap fibroatheroma (TCFA)*
- *OCT can visualize plaque rupture & thrombosis in vivo*



Symptomatic Plaque Rupture: STEMI



Asymptomatic Witnessed Plaque Rupture





Asymptomatic Witnessed Plaque Rupture





Plaque rupture

Asymptomatic Witnessed Plaque Rupture





Empty cavity

Asymptomatic Witnessed Plaque Rupture



Thrombus, filling rupture defect

Asymptomatic Witnessed Plaque Rupture



Symptomatic Witnessed Plaque Rupture Periprocedural

Case Example: 64y, male, stable angina CCS 3



Pre



Direct stenting
3.5mm/12mm;18atm
Vasospasm, haziness,
slow flow




Postdilatation
4.0mm/8mm;18atm

Post PCI: Troponin 53ng/L
(ULN: 13ng/L)

Symptomatic Witnessed Plaque Rupture Periprocedural

A. NIRS
B. OCT pre-procedural




Pre-intervention imaging: lipid-rich culprit lesion




Symptomatic Witnessed Plaque Rupture Periprocedural



C. OCT stent
implantation




Post stent: Strut malapposition proximal
Tissue protrusion within stent



Symptomatic Witnessed Plaque Rupture Periprocedural



D. OCT post-dilation




Postdilation: Disruption of lipid-rich plaque



Symptomatic Witnessed Plaque Rupture Periprocedural



D. OCT post-dilation




Postdilation: Disruption of lipid-rich plaque




Symptomatic Witnessed Plaque Rupture Periprocedural



1. Chemogram/L-mode 2. Proximal edge 3. Lipid-rich plaque 4. Lipid-rich plaque 5. Lipid-rich plaque 6. Lipid-rich plaque 7. Distal Edge



Presence of lipid rich thin cap fibro-atheroma




Disruption of lipid rich thin cap fibro-atheroma



Plaque Prone to Rupture

Inflamed, thin-cap fibroatheroma (TCFA)

- ✓ Lipid-rich, atheromatous core
- ✓ Thin fibrous cap, with
- ✓ Macrophage and lymphocyte infiltration



- OCT can visualize the pathologic substrate in patients



- OCT can visualize the pathologic substrate in patients
- Standardization of nomenclature & definitions of IV OCT findings

Consensus Standards for Acquisition, Measurement, and Reporting of Intravascular Optical Coherence Tomography Studies

A Report From the International Working Group for Intravascular
Optical Coherence Tomography Standardization and Validation

Guillermo J. Tearney, MD, PhD, *Writing Committee Co-Chair,**
Evelyn Regar, MD, PhD, *Writing Committee Co-Chair,†* Takashi Akasaka, MD, *Writing Committee Co-Chair,‡*
Tom Adriaenssens, MD, Peter Barlis, MD, Hiram G. Bezerra, MD, Brett Bouma, PhD,
Nico Bruining, PhD, Jin-man Cho, MD, PhD, Saqib Chowdhary, PhD, Marco A. Costa, MD, PhD,
Ranil de Silva, MD, PhD, Jouke Dijkstra, PhD, Carlo Di Mario, MD, PhD, Dariusz Dudeck, MD, PhD,
Erlin Falk, MD, PhD, Marc D. Feldman, MD, Peter Fitzgerald, MD, Hector Garcia, MD,
Nieves Gonzalo, MD, Juan F. Granada, MD, Giulio Guagliumi, MD, Niels R. Holm, MD,
Yasuhiro Honda, MD, Fumiaki Ikeno, MD, Masanori Kawasaki, MD, Janusz Kochman, MD, PhD,
Lukasz Koltowski, MD, Takashi Kubo, MD, PhD, Tenuyoshi Kume, MD, Hiroyuki Kyono, MD,
Cheung Chi Simon Lam, MD, Guy Lamouche, PhD, David P. Lee, MD, Martin B. Leon, MD,
Akiko Maehara, MD, Olivia Manfrini, MD, Gary S. Mintz, MD, Kiyochi Mizuno, MD,
Marie-angèle Morel, MD, Secemantini Nadkarni, PhD, Hiroyuki Okura, MD, Hiromasa Otake, MD,
Arkadiusz Pietrasik, MD, Francesco Prati, MD, Lorenz Räber, MD, Maria D. Radu, MD,
Johannes Rieber, MD, Maria Riga, MD, Andrew Rollins, PhD, Mireille Rosenberg, PhD, Vasile Sirbu, MD,
Patrick W. J. C. Serruys, MD, PhD, Kenci Shimada, MD, Toshiro Shinke, MD, Junya Shite, MD,
Eliot Siegel, MD, Shinjo Sonada, MD, Melissa Suter, PhD, Shigeho Takarada, MD, PhD,
Atsushi Tanaka, MD, PhD, Mitsuyasu Terashima, MD, Thim Troels, MD, PhD, Shiro Uemura, MD, PhD,
Giovanni J. Ughi, PhD, Heleen M.M. van Beusekom, PhD, Antonius F.W. van der Steen, PhD,
Gerrit-Ann van Es, PhD, Gijs van Soest, PhD, Renu Virmani, MD, Sergio Waxman, MD,
Neil J. Weissman, MD, Giora Weisz, MD

Boston, Massachusetts; Rotterdam, the Netherlands; and Wakayama, Japan



OCT Assessment of Vulnerability

Standardization of Nomenclature & Definitions

Fibroatheroma (A)


lesion with an OCT-delineated fibrous cap and a lipid pool

OCT thin cap fibroatheroma (C)


an OCT-delineated necrotic core with an overlying fibrous cap where the min. thickness is less than a predetermined threshold

Fibrous cap

is a tissue layer, which is often signal-rich, overlying a lipid pool, necrotic core, or calcium.



Is this good enough?





OCT Pifalls

Moderate positive predictive value!



Accuracy of OCT, Grayscale IVUS, and Their Combination for the Diagnosis of Coronary TCFA



An Ex Vivo Validation Study

Kenichi Fujii, MD,* Hiroyuki Hao, MD,† Masahiko Shibuya, MD,* Takahiro Imanaka, MD,* Masashi Fukunaga, MD,*
Kojiro Miki, MD,* Hiroto Tamaru, MD,* Hisashi Sawada, MD,* Yoshiro Naito, MD,* Mitsumasa Ohyanagi, MD,‡
Seiichi Hirota, MD,‡ Tohru Masuyama, MD*



OCT Pifalls

Moderate positive predictive value!




Accuracy of OCT, Grayscale IVUS, and Their Combination for the Diagnosis of Coronary TCFA



An Ex

Kenichi
Kojiro M
Seichi F

Diagnostic Accuracy of OCT for TCFA





OCT Pifalls

Moderate positive predictive value!




Accuracy of OCT, Grayscale IVUS, and Their Combination for the Diagnosis of Coronary TCFA



An Ex Vivo Validation Study

Kenichi Fujii, MD,* Hiroyuki Hao, MD,† Masahiko Shibuya, Kojiro Miki, MD,* Hiroto Tamaru, MD,* Hisashi Sawada, M, Seiichi Hirota, MD,† Tohru Masuyama, MD*

Total of 685 Focal Plaques





OCT Pitfalls

OCT TCFA - Comparison to Histologic Classification



OCT	Fibrous tissue area		
	Thick <i>160-910 μm</i>	Medium-thin <i>90-140 μm</i>	Thin <i>30-60 μm</i>
	38	9	13
Histo	<i>25 Thick fibrous cap</i> <i>8 Fibro-calcific</i> <i>5 Fibrous</i>		<i>11 Thin fibrous cap</i> <i>11 Fibro-calcific</i>



to 2 main limitations of OCT imaging. First, the penetration depth of OCT is limited to 1 to 2 mm, which does not allow the accurate detection of signal-poor areas possibly representing lipid pools or calcium behind fibrous tissue. This may generate false-positive fibrous plaques, false-negative fibrocalcific plaques, and false-negative thick-cap fibroatheromas. Second, OCT analysis often confuses the presence of lipid pools with that of calcium deposits, or vice versa. As



OCT Pitfalls

Confusion of Lipid with Calcium




OCT	Calcified lesion 	Lipid-rich lesion 	Thin 30-60 μm
Histo	Sharply delineated borders	Diffuse borders	13 <i>thin fibrous cap</i> <i>pro-calcific</i>

ing. First, the penetration
mm, which does not allow
poor areas possibly repre-
behind fibrous tissue. This
us plaques, false-negative
negative thick-cap fibroathe-
romas. Second, OCT analysis often confuses the presence of
lipid pools with that of calcium deposits, or vice versa. As



OCT Pitfalls

Artefacts: Macrophage scattering



The region of thickened intima appears as a TCFA due to strong scattering & shadowing by macrophages.




OCT Pifalls

Artefacts cause misclassification!

Incidence of artefacts in clinical setting

Category	# observations		
	Pullbacks	Sections	Frames
	Total 37		Total 4597
1: Superficial attenuation	16	26	94
2: Tangential signal dropout	15	27	145
3: Catheter shadowing	12	21	35
4: Axial PSF tail	0	0	0
5: Proximity brightening	12	17	313

Can we predict rupture?






In-Vivo Fibrous Cap Detection Pilot: Patient Characteristics

n= 23 patients



Age (yrs)	61±11
Male	18
Clinical presentation	
Silent ischemia	1
Stable angina	18
Unstable angina	4
Extent of CAD	
1 VD	14
2 VD	5
3 VD	4
Previous MI	6
Hypertension	13
Dyslipidemia	11
Current smoker	5
IDDM	2
Pos. family history	6

Target Vessel (%)








In-Vivo Fibrous Cap Detection Pilot: Case Example: Non-Culprit Lesion



TCFA



dist





In-Vivo Fibrous Cap Detection Pilot: Case Example: Non-Culprit Lesion

n=7 (6 Pts)



3 Pts: Unstable angina
2 Pts: ACS two weeks earlier
1 Pt: Stable angina

TCFA





In-Vivo Fibrous Cap Detection Pilot: Case Example: Non-Culprit Lesion



n=7 (6 Pts)



Cap thickness: 0.19 ± 0.05 mm

Circumf. extent: $103 \pm 49^\circ$

TCFA





Pilot Results:

Clinical Outcome at 24 Months FUP

$n=23$

Remote from culprit

Cap thickness: 0.19 ± 0.05 mm

Circumferential extent: $103 \pm 49^\circ$

Thin Fibrous Cap 6 Pts


Death	0
Acute myocardial infarction	0
Revascularisation	1
Hospitalization	1
Angina status	5
CCS I	1
CCS II	0
CCS III	0
CCS IV	0

*Repeat-PCI
for in-stent
restenosis*


*Uneventful
hip endo-
prosthesis*

OCT Assessment of Vulnerability From Morphology to Symptomatic Rupture Is There a Missing Link?

Trigger?



OCT Assessment of Vulnerability From Morphology to Symptomatic Rupture Is There a Missing Link?




F

OCT Assessment of Vulnerability

From Morphology to Symptomatic Rupture

Is There a Missing Link?



Strain

OCT Assessment of Vulnerability From Morphology to Symptomatic Rupture Is There a Missing Link?

Intra-plaque Hemorrhage

Leaking from **vasa vasorum** or
shoulders of plaque with
extensive **angiogenesis**
Fissure of fibrous cap



Virmani, et al
ATVB 2000; 20: 1262

- OCT can visualize in vivo features for vulnerable plaque: TFCA (neovascularization, calcified nodule, thrombosis)
- High sensitivity, specificity, & negative predictive value
- Positive predictive value is moderate!
- Further validation needed!!
 - Diagnostic accuracy of plaque features
 - Interstudy/ inter-OCT system/ interobserver variability



OCT: Future Directions Tissue Characterization: Optical Attenuation Imaging

- *Imaging: C7XR, Visipaque flush 3ml/s*
- *Lumen segmentation*
- *Speckle filtering*
- *Analyze using single scattering model; window length > 200 μm*

$$\langle i_d(r) \rangle = I_0 \cdot T_{\text{cath}}(r) \cdot \hat{S}(r) \cdot \exp(-\mu_t r)$$

$T_{\text{cath}}(r)$: *catheter axial PSF*

$\hat{S}(r)$: *roll-off correction*



OCT:

Future Directions Tissue Characterization: Optical Attenuation Imaging

Relation between tissue type & attenuation coefficient


Fibrous	low
Calcium	low
Necrotic core	HIGH
Macrophages	very HIGH



OCT: Future Directions Tissue Characterization: Optical Attenuation Imaging




H&E



mac




smc






OCT: Future Directions Tissue Characterization: Optical Attenuation Imaging





OCT: Future Directions Tissue Characterization: Optical Attenuation Imaging




Courtesy
M. Gnanadesigan
T. Kameyama



OCT:

Future Directions Tissue Characterization: Polarization Sensitive Imaging



Intensity


Local Retardation (φ)Degree of Polarization
(DOP)
 φ
DOP

- Local retardation (high) reveals collagen
- DOP (low) hints at foam cells, lipid, macrophages


In-vivo human coronary; in cooperation with Villinger M, Bouma B, MGH Boston, USA



OCT: Future Directions Tissue Characterization: Polarization Sensitive Imaging





Local Retardation (φ)







OCT: Future Directions Tissue Characterization: Polarization Sensitive Imaging



OCT: Future Directions Ultrafast “Heartbeat” OCT

Conventional OCT: 100 fps & 20 mm/s pullback speed (200 μ m frame pitch).



Heartbeat OCT: 3200 fps & 100 mm/s pullback speed (31 μ m frame pitch).

Wang T. van Soest G. presented at EuroPCR 2014

Wang T.. et al. Optics letters 38, 1715-1717 (2013).

OCT:
**Future Directions Ultrafast
“Heartbeat” OCT**



Wang T. van Soest G. presented at EuroPCR 2014

Wang T.. et al. Optics letters 38, 1715-1717 (2013).



optics in cardiology

April 6/7
2017

Rotterdam
The Netherlands

www.opticsincardiology.org

Erasmus MC
University Medical Center Rotterdam



Thoraxcenter

organizers
Evelyn Regar
Gijs van Soest



@OiCconf

Thank you for your attention!

PhD Students & Guest Researchers



Interventional Cardiology

*R. Diletti
R.J. van Geuns
J. Daemen
P. de Jaegere
N. van Mieghem
F. Zijlstra*

Experimental Cardiology

H. van Beusekom

Hemodynamics Laboratory

*J. Wentzel
F. Gijsen*

Bioengineering

*G. van Soest
A.F.W. van der Steen*

Imaging Group

*N. Bruining
K. Sihan*